Eli Lilly announced on Wednesday that it would expand a program that restricts patient expenses at $35 per month and reduce the cost of its most frequently prescribed insulin treatments by 70%.
Although most individuals with diabetes can obtain insulin through the present healthcare system, not everyone can afford it, and this needs to change, according to David Ricks, chair and CEO of Eli Lilly.
“The dramatic price reductions we’re announcing today should really help Americans with diabetes,” he continued.
